explore -WSS

explore

author：explore 2025-09-30 12:57:13 - browse：62

Christine Kao/STAT

The Food and Drug Administration’s approval on Friday of two gene therapies for sickle cell disease sets up what could be an intense competition between Bluebird Bio, maker of Lyfgenia, and the partnership of Vertex Pharmaceuticals and CRISPR Therapeutics, whose drug is Casgevy.

For the first time, physicians and patients will have a choice of potentially curative treatments for an inherited disease that affects nearly 100,000 Americans.

The Vertex/CRISPR team would seem to have the edge. As the first CRISPR-based therapy, Casgevy has the advantage of being powered by the latest and buzziest biological technology, though some physicians and patients may be more comfortable with the lentiviral vector technology behind Lyfgenia, which dates back to the 1990s — even with a “black box” warning of a risk of blood cancer added to its label.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： ActiGraph execs on goal of drug approvals with digital endpoints

WSS

Living with Hashimoto's and celiac disease, and med school, too

Printout prescription drug information shouldn’t go digital

Dog Aging Project founders on what lies ahead after losing funding

Medicare drug price lawsuits could be good politics for Biden

Hilary expected to bring catastrophic, life

CVS is on a mission to consolidate health care. Will it work?

hotspot

explore

entertainment

The cancer drug shortage isn’t new — and neither are the solutions

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Trump demands the U.S. pay no more for drugs than other countries … again

Update the Apgar Score to remove skin color

Continuity nursing helped my family in our darkest PICU moments

FDA approves first treatment for ultra

Hepatitis C has a cure — but many Americans still lack access to it

New definition of a human embryo proposed amid rapid advances

focus

ActiGraph execs on goal of drug approvals with digital endpoints

Maisha Meds is a PBM, but don't call it that

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Congress must give Medicare recipients genetic counseling access

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Trump's false claims about Georgia's 2020 election long debunked

hotspot

knowledge

explore

knowledge